Summary of Study ST001303
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000884. The data can be accessed directly via it's Project DOI: 10.21228/M8DX2P This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001303 |
Study Title | TGF-Beta 3 heterozygous mice |
Study Type | Mice nephropathy in lipotoxic model |
Study Summary | Transforming growth factor β (TGFβ) family comprises the main player in the development of fibrosis including three isoforms: TGFβ1, TGFβ2 and TGFβ3. TGFβ3 may play an antifibrotic role at the renal level, counteracting the role of TGFβ1, using a mouse model heterozygous for the TGFβ3 gene (TGFβ3+/-). Partial deletion of TGFβ3 causes in the mice albuminuria, loss of glomerular filtration rate, accelerated fibrosis, epithelial-to-mesenchymal transition and increment of glomerular basement membrane thickening. |
Institute | University Rey Juan Carlos |
Department | Basics Science of Health |
Last Name | Lanzon |
First Name | Borja |
Address | Avenida de Atenas S/N |
borja.lanzon@urjc.es | |
Phone | 663692554 |
Submit Date | 2019-12-19 |
Num Groups | 2 |
Total Subjects | 14 |
Num Males | 14 |
Raw Data Available | Yes |
Raw Data File Type(s) | d |
Analysis Type Detail | GC-MS/LC-MS |
Release Date | 2020-03-03 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
Analysis ID | AN002169 | AN002170 | AN002171 |
---|---|---|---|
Analysis type | MS | MS | MS |
Chromatography type | Reversed phase | Reversed phase | GC |
Chromatography system | Agilent 1290 Infinity II | Agilent 1290 Infinity II | Agilent 7890B |
Column | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) | Agilent DB5-MS (30m x 0.25mm, 0.25um) |
MS Type | ESI | ESI | EI |
MS instrument type | QTOF | QTOF | GC QTOF |
MS instrument name | Agilent 6545 | Agilent 6545 | Agilent 7890A |
Ion Mode | POSITIVE | NEGATIVE | POSITIVE |
Units | Area | Area | Area |
Chromatography:
Chromatography ID: | CH001587 |
Chromatography Summary: | LC-MS (+) |
Instrument Name: | Agilent 1290 Infinity II |
Column Name: | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
Column Temperature: | 60 |
Flow Gradient: | gradient started at 82% phase B, increasing to 90% B in 17 min. The gradient then increased to 100% B by minute 18 and was maintained for 2 minutes until 20 min. The starting condition was returned to by 21.5 min, followed by an 8.5 min reequilibration time, taking the total run time to 30 min |
Flow Rate: | 0.5 mL/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 85% methanol/15% isopropanol; 0.1% formic acid |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH001588 |
Chromatography Summary: | LC-MS (-) |
Instrument Name: | Agilent 1290 Infinity II |
Column Name: | Poroshell 120 EC-C8 (100 x 2.1mm,2.5um) |
Column Temperature: | 60 |
Flow Gradient: | gradient started at 82% phase B, increasing to 90% B in 17 min. The gradient then increased to 100% B by minute 18 and was maintained for 2 minutes until 20 min. The starting condition was returned to by 21.5 min, followed by an 8.5 min reequilibration time, taking the total run time to 30 min |
Flow Rate: | 0.5 mL/min |
Solvent A: | 100% water; 0.1% formic acid |
Solvent B: | 85% methanol/15% isopropanol; 0.1% formic acid |
Chromatography Type: | Reversed phase |
Chromatography ID: | CH001589 |
Chromatography Summary: | GC-MS |
Instrument Name: | Agilent 7890B |
Column Name: | Agilent DB5-MS (30m x 0.25mm, 0.25um) |
Chromatography Type: | GC |